CAS: 1356962-20-3; N-(4-(4-Aminopiperidin-1-yl)-2-Methoxyphenyl)-5-Chloro-4-(1H-Indol-3-yl)Pyrimidin-2-Amine

上下游产品

3-(2,5-dichloropyrimidine-4-yl)-1H-indole tert-butyl (1-(4-amino-3-methoxyphenyl)piperidin-4-yl)carbamate

3-(2,5-二氯嘧啶-4-基)-1H-吲哚,Tert-Butyl (1-(4-Amino-3-Methoxyphenyl)Piperidin-4-yl)Carbamate置于对甲苯磺酸体系中,用 戊醇 用作溶剂,化学反应 1.0H,以30%的收率获得n-[4-(4-氨基-1-哌啶基)-2-甲氧基苯基]-5-氯-4-(1H-吲哚-3-基)-2-嘧啶胺
参考文献:Chemical Compounds
标题:Chemical Compounds
摘要:本发明涉及公式(i)和/或公式(ia)的化合物,以及它们的盐,制药组合物,使用方法和制备方法.这些化合物抑制alk激酶活性,因此可用于治疗癌症.

专利信息

专利号:US-2025289827-A1
优先权日:2022-12-02
标 题:Morphic forms of a mutant braf degrader and methods of manufacture thereof
发明人：YU ROBERT T; HE MINSHENG; SCHNADERBECK MATTHEW J; KREGER BRIDGET; POLLOCK ROY MACFARLANE; JIANG SIYI; LI MEIQI; CHEN BOLU; LU JIANNAN
权利人:C4 THERAPEUTICS INC
摘要:Advantageous isolated morphic forms of (3R)-3-[6-[2-cyano-3-[[ethyl(methyl)sulfamoyl]amino]-6-fluorophenoxy]-4-oxoquinazolin-3-yl]-8-[2-[1-[3-(2,4-dioxo-1,3-diazinan-1-yl)-5-fluoro-1-methylindazol-6-yl]-4-hydroxypiperidin-4-yl]acetyl]-1-oxa-8-azaspiro[4.5]decane (Compound 1), which is a mutant BRAF degrader, and methods to prepare Compound 1 morphic forms for therapeutic applications are provided in the invention. The invention also provides improved methods for the synthesis of Compound 1, new pharmaceutical compositions comprising Compound 1, and new uses of Compound 1.